Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Civacir in Liver Transplant Recipients
NCT00473824Phase 2Terminated
- Sponsor
- ADMA Biologics, Inc.
- Start
- May 2007
- Primary completion
- Feb 2009
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Nabi-HB Intravenous in hepatitis C (HCV) (2 arms), sponsored by ADMA Biologics, Inc. Primary endpoints: Post Transplant Reduction in Viral Load at 6 months, Safety of Civacir at 48 weeks and 1 more. Started May 2007; status: terminated.
02
Drugs
Nabi-HB Intravenous
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00473824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00473824.